DelveInsight's "Crohn’s Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth ...

In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on UCB SA (0NZT – Research Report), with a price target of ...

ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) and West Pharmaceutical Services (NYSE:WST – Get Free Report) are both medical companies, but which is the superior business? We will compare the two ...

the company's current head of Biopharma Brands and Solutions, to be its new leader from 2015. "UCB has three promising products in phase III: brivaracetam for epilepsy, lupus treatment epratuzumab ...

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to the class leader.

Multiple biopharma companies have recently offloaded their mature or low-margin businesses in China. UCB in August unveiled a $680 million deal to divest its mature neurology and allergy business ...

Kaiser Permanente-backed biopharma CAMP4 raises $75 mln in US IPO ... 2024 Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage ...

UCB revealed Roche’s decision while announcing the acceptance ... In April, the Cambridge, Mass.–based biopharma announced it would discontinue development of dalzanemdor in Parkinson’s disease after ...

Theravance Biopharma R&D, Boehringer-Ingelheim, Synergy Pharmaceuticals, Toplvert Pharma, UCB and Lilly; has served on scientific advisory boards for Celgene, Janssen Biotech, MedImmune, Takeda, ...

Objective Effective medical therapy and validated trial outcomes are lacking for small bowel Crohn’s disease (CD) strictures. Histopathology of surgically resected specimens is the gold standard for ...